Pembrolizumab-induced colitis, though less frequent than with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, can range in severity from mild to life-threatening, necessitating prompt recognition and management to prevent severe outcomes such as bowel perforation or even death [1,2]. This evidence concerns the gene CTLA4 and colitis.